Bisphosphonate-Associated Osteonecrosis of the Jaws

Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism: Seventh Edition

Volumn , Issue , 2009, Pages 505-509

  Treister, Nathaniel S ^a   Woo, Sook Bin ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD SCHOOL OF DENTAL MEDICINE   (United States)

Author keywords

Bisphosphonates; Oral lesions; Oral medicine; Osteonecrosis

Indexed keywords

EID: 79551719001     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470623992.ch107     Document Type: Chapter

References (50)

1. Migliorati CA 2003 Bisphosphanates and oral cavity avascular bone necrosis. J Clin Oncol 21:4253-4254.
2. Marx RE 2003 Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: A growing epidemic. J Oral Maxillofac Surg 61:1115-1117.
3. Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL 2004 Osteonecrosis of the jaws associated with the use of bisphosphonates: A review of 63 cases. J Oral Maxillofac Surg 62:527-534.
4. Marx RE, Cillo JE. Ulloa JJ 2007 Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment. J Oral Maxillofac Surg 65:2397-2410.
5. Yarom N, Yahalom R, Shoshani Y, Hamed W, Regev E, Elad S 2007 Osteonecrosis of the jaw induced by orally administered bisphosphonates: Incidence, clinical features, predisposing factors and treatment outcome. Osteoporos Int 18:1363-1370.
6. Polizzotto MN, Cousins V, Schwarer AP 2006 Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 132:114.
7. American Association of Oral and Maxillofacial Surgeons 2007 American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws. J Oral Maxillofac Surg 65:369-376.
8. Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S, McCauley LK, McGowan J, McKee MD, Mohla S, Pendrys DG, Raisz LG, Ruggiero SL, Shafer DM, Shum L, Silverman SL, Van Poznak CH, Watts N, Woo SB, Shane E 2007 Bisphosphonate-associated osteonecrosis of the jaw: Report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479-1491.
9. Marx RE 1983 Osteoradionecrosis: A new concept of its pathophysiology. J Oral Maxillofac Surg 41:283-288.
10. Peters E, Lovas GL, Wysocki GP 1993 Lingual mandibular sequestration and ulceration. Oral Surg Oral Med Oral Pathol 75:739-743.
11. Novak MJ 1999 Necrotizing ulcerative periodontitis. Ann Periodontal 4:74-78.
12. Houston JP, McCollum J, Pietz D, Schneck D 2002 Alveolar osteitis: A review of its etiology, prevention, and treatment modalities. Gen Dent 50:457-163.
13. Enwonwu CO, Falkler WA Jr, Phillips RS 2006 Noma (cancrum oris). Lancet 368:147-156.
14. Shane E, Goldring S, Christakos S, Drezner M, Eisman J, Silverman S, Pendrys D 2006 Osteonecrosis of the jaw: More research needed. J Bone Miner Res 21:1503-1505.
15. Huja SS, Fernandez SA, Hill KJ, Li Y 2006 Remodeling dynamics in the alveolar process in skeletally mature dogs. Anat Ree A Discov Mol Cell Evol Biol 288:1243-1249.
16. Wood J, Bonjean K, Ruetz S, Bellahcene A, Devy L, Foidart JM, Castronovo V, Green JR 2002 Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 302:1055-1061.
17. Santini D, Vincenzi B, Dicuonzo G, Avvisati G, Massacesi C, Bat-tistoni F, Gavasci M, Rocci L, Tirindelli MC, Altomare V. Toc-chini M, Bonsignori M, Tonini G 2003 Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 9:2893-2897.
18. Groetz KA, Al-Nawas B 2006 Persisting alveolar sockets-a radiologic symptom of BP-ONJ? J Oral Maxillofac Surg 64:1571-1572.
19. Zervas K, Verrou E, Teleioudis Z, Vahtsevanos K, Banti A, Mi-hou D, Krikelis D, Terpos E 2006 Incidence, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma: A single-centre experience in 303 patients. Br J Haematol 134:620-623.
20. Dimopoulos MA, Kastritis E, Anagnostopoulos A, Melakopoulos I, Gika D, Moulopoulos LA, Bamia C, Terpos E, Tsionos K, Bamias A 2006 Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: Evidence of increased risk after treatment with zoledronic acid. Haematologica 91:968-971.
21. Marx RE, Sawatari Y, Fortin M, Broumand V 2005 Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567-1575.
22. Pozzi S, Marcheselli R. Sacchi S, Baldini L, Angrilli F, Pennese E, Quarta G, Stelitano C, Caparotti G, Luminari S, Musto P, Natale D, Broglia C, Cuoghi A, Dini D, Di Tonno P, Leonardi G, Pianezze G, Pitini V, Polimeno G, Ponchio L, Masini L, Musso M, Spriano M, Pollastri G 2007 Bisphosphonate-associated osteonecrosis of the jaw: A review of 35 cases and an evaluation of its frequency in multiple myeloma patients. Leuk Lymphoma 48:5664.
23. Mavrokokki T, Cheng A, Stein B, Goss A 2007 Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. J Oral Maxillofac Surg 65:415-123.
24. Woo SB, Hande K, Richardson PG 2005 Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102.
25. Maerevoet M, Martin C, Duck L 2005 Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102.
26. Bamias A, Kastritis E, Bamia C, Moulopoulos LA, Melakopoulos I, Bozas G, Koutsoukou V, Gika D, Anagnostopoulos A, Pa-padimitriou C, Terpos E, Dimopoulos MA 2005 Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: Incidence and risk factors. J Clin Oncol 23:8580-8587.
27. Durie BG, Katz M, Crowley J 2005 Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 353:99-102.
28. Murad OM, Arora S, Farag AF, Guber HA 2007 Bisphosphonates and osteonecrosis of the jaw: A retrospective study. Endocr Pract 13:232-238.
29. Woo SB, Hellstein JW, Kalmar JR 2006 Narrative [corrected] review: Bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 144:753-761.
30. 2005 Alendronate (Fosamax) and risedronate (Actonel) revisited. Med Lett Drugs Ther 47:33-35.
31. Agarwala S, Jain D, Joshi VR, Sule A 2005 Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the hip. A prospective open-label study. Rheumatology (Oxford) 44:352359.
32. Chiandussi S, Biasotto M, Dorè F, Cavalli F, Cova MA, Di Lenar-da R 2006 Clinical and diagnostic imaging of bisphosphonateassociated osteonecrosis of the jaws. Dentomaxillofac Radiol 35:236-243.
33. Catalano L, Del Vecchio S, Petruzziello F, Fonti R, Salvatore B, Martorelli C, Califano C, Caparrotti G, Segreto S, Pace L, Rotoli B 2007 Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosis. Ann Hematol 86:415-423.
34. Ruggiero SL, Fantasia J, Carlson E 2006 Bisphosphonate-related osteonecrosis of the jaw: Background and guidelines for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 102:433-441.
35. Bedogni A, Saia G. Ragazzo M, Bettini G, Capelli P, D'Alessandro E, Nocini PF, Russo LL, Lo Muzio L, Blandamura S 2007 Bisphosphonate-associated osteonecrosis can hide jaw metastases. Bone 41:942-945.
36. Merigo E. Manfredi M, Meleti M, Corradi D, Vescovi P 2005 Jaw bone necrosis without previous dental extractions associated with the use of bisphosphonates (pamidronate and zoledronate): A four-case report. J Oral Pathol Med 34:613-617.
37. Badros A, Weikel D, Salama A, Goloubeva O, Schneider A, Rapoport A, Fenton R, Gahres N, Sausville E, Ord R, Meiller T 2006 Osteonecrosis of the jaw in multiple myeloma patients: Clinical features and risk factors. J Clin Oncol 24:945-952.
38. Hansen T, Kunkel M, Weber A, James Kirkpatrick C 2006 Osteonecrosis of the jaws in patients treated with bisphosphonates- histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35:155-160.
39. Russo T 2005 Agents of actinomycosis. In: Mandell G, Bennett J, Dolin R (eds.) Principles and Practice of Infectious Diseases, 6th ed. Elsevier Churchill Livingston, Philadelphia, PA. USA, pp. 2924-2934.
40. Migliorati CA. Casiglia J, Epstein J, Jacobsen PL, Siegel MA, Woo SB 2005 Managing the care of patients with bisphosphonate-associated osteonecrosis: An American Academy of Oral Medicine position paper. J Am Dent Assoc 136:1658-1668.
41. Magopoulos C, Karakinaris G, Telioudis Z, Vahtsevanos K, Dimi-trakopoulos I, Antoniadis K, Delaroudis S 2007 Osteonecrosis of the jaws due to bisphosphonate use. A review of 60 cases and treatment proposals. Am J Otolaryngol 28:158-163.
42. Freiberger JJ, Padilla-Burgos R, Chhoeu AH, Kraft KH, Boneta O, Moon RE, Piantadosi CA 2007 Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw: A case series. J Oral Maxillofac Surg 65:1321-1327.
43. Vescovi P, Merigo E, Meleti M, Manfredi M 2006 Bisphosphonate-associated osteonecrosis (BON) of the jaws: A possible treatment? J Oral Maxillofac Surg 64:1460-1462.
44. Adornato MC, Morcos I, Rozanski J 2007 The treatment of bisphosphonate-associated osteonecrosis of the jaws with bone resection and autologous platelet-derived growth factors. J Am Dent Assoc 138:971-977.
45. Agrillo A, Ungari C, Filiaci F, Priore P, Iannetti G 2007 Ozone therapy in the treatment of avascular bisphosphonate-related jaw osteonecrosis. J Craniofac Surg 18:1071-1075.
46. Harper RP, Fung E 2007 Resolution of bisphosphonate-associated osteonecrosis of the mandible: Possible application for intermittent low-dose parathyroid hormone [rhPTH(l-34)]. J Oral Maxillofac Surg 65:573-580.
47. Ruggiero SL, Gralow J, Marx RE, Hoff AO, Schubert MM, Huryn JM, Toth B, Damato K, Valero V 2006 Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patinets with cancer. J Oncol Pract 2:7-14.
48. Lacy MQ, Dispenzieri A, Gertz MA, Greipp PR, Gollbach KL, Hayman SR, Kumar S, Lust JA, Rajkumar SV, Russell SJ, Witzig TE, Zeldenrust SR, Dingli D, Bergsagel PL, Fonseca R, Reeder CB, Stewart AK, Roy V, Dallon RJ, Carr AB, Kademani D, Keller EE, Viozzi CF, Kyle RA 2006 Mayo clinic consensus statement for the use of bisphosphonates in multiple myeloma. Mayo Clin Proc 81:1047-1053.
49. Kyle RA. Yee GC, Somerfield MR, Flynn PJ, Halabi S, Jagannath S. Orlowski RZ, Roodman DG, Twilde P, Anderson K 2007 American Society of Clinical Oncology 2007 clinical practice guideline update on the role of bisphosphonates in multiple myeloma. J Clin Oncol 25:2464-2472.
50. Weitzman R, Sauter N, Eriksen EF, Tarassoff PG, Lacerna LV, Dias R, Altmeyer A, Csermak-Renner K, McGrath L, Lantwicki L, Hohneker JA 2007 Critical review: Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients-May 2006. Crit Rev Oncol Hematol 62:148152.